Is it better to take a “stronger” disease modifying therapy such as Tysabri or a “weaker” and more conservative disease modifying therapy? Many people who have low baseline disability prefer a cautious approach, but this study shows that the “stronger” drugs are actually better if taken by less disabled people early on

The article I am discussing: https://www.mdpi.com/1424-8247/14/2/8…